Hologic agreed to be acquired by private equity firms Blackstone and TPG in a deal valuing the company at up to $18.3 billion. The buyers will pay $76 per share plus up to $3 per share in contingent value rights tied to breast‑health revenue targets. Hologic’s board unanimously approved the transaction and implemented a 45‑day go‑shop window. The deal pulls a major diagnostics and women’s health company out of public markets and secures financing from a syndicate of global banks and sovereign investors, including ADIA and GIC. Management said the buyout will let Hologic invest privately in product innovation and growth while retaining its brand and headquarters in Massachusetts. Market implications include consolidation in diagnostics and potential repricing of comparable med‑tech assets, while customers and labs will monitor how private ownership affects product roadmaps and reimbursement negotiation strategies.